Qiagen N.V.
Netherlands · NL0012169213 · reports in USD · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +5.7% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 11% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 62% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $2.1B | $2.0B | $2.0B | $2.1B |
| Operating profit | $533M | $413M | $117M | $468M |
| Earnings per share | $2.53 | $2.12 | $0.71 | $2.01 |
| Dividend per share | n/a | n/a | n/a | $0.25 |
| Cash from operations | $751M | $493M | $708M | $692M |
| Capital spending | $56M | $41M | $68M | $77M |
| Cash | $730M | $667M | $663M | $839M |
| Total assets | $6.4B | $6.2B | $5.8B | $6.3B |
| Equity | $3.4B | $3.9B | $3.7B | $3.9B |
What they do
In the company's own words, from the annual report.
1. Corporate Information, Basis of Presentation and Statement of ComplianceCorporate Information QIAGEN N.V. is a public limited liability company (naamloze vennootschap) under Dutch law with a registered office at Hulsterweg 82, 5912 PL Venlo, The Netherlands. QIAGEN N.V., a Netherlands holding company, and subsidiaries (we, our or the Company) is a global leader in Sample to Insight solutions, that enable customers to extract and analyze molecular information from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. We serve more than 500,000 custo
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.